Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat

✍ Scribed by Cosimo Sperti; Carmelo Militello; Roubik Behboo; Edwin Khajeturian; Sergio Pedrazzoli; Antonio Perasole; Rita Alaggio; Lucio Rovati

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 567 KB
• Volume: 57
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930570105

✦ Synopsis

The effects of the cholecystokinin (CCK)-analogue, caerulein, and CCKreceptor antagonist lorglumide (CR-1409) on pancreatic carcinogenesis induced by 7,12-dimethylbenz(a)anthracene (DMBA) were studied. One hundred thirty rats were divided into the following 10 treatment groups: group 1, DMBA (2-3 mg); group 2, DMBA + caerulein (5 bg/kg); group 3, DMBA + caerulein + CR-1409 (12 mg/kg); group 4, caerulein + DMBA; group 5, caerulein + CR-1409 + DMBA; group 6, DMBA + CR-1409; group 7, CR-1409 + DMBA; group 8, caerulein; group 9, CR-1409; and group 10, sham operation + saline. DMBA was surgically implanted into the pancreas. Caerulein and/or CR-1409 was administered twice daily for 15 days after (in groups 2, 3, and 6) or before (in groups 4, 5 , and 7) DMBA implantation. Six months after carcinogen administration, all rats were sacrificed and autopsied. The incidence of pancreatic cancer appeared significantly (P < 0.001) increased when caerulein was administered following DMBA implantation. CR-1409 significantly inhibited (P < 0.02) caerulein effects and reduced tumor growth when injected after carcinogen exposure.